A UMass Medical School pharmacy expert will present on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and their potential use for managing cholesterol at Asembia’s 2016 Specialty Pharmacy Summit May 2-6 in Las Vegas.
“An Evidence-Based Assessment of PCSK9 Inhibitors & the Future of Hypercholesterolemia Management,” will be presented by Mark Tesell, PharmD, BCPS, a clinical consultant pharmacist in Clinical Pharmacy Services, a unit within UMass Medical School’s Commonwealth Medicine division, from 11 to 11:45 a.m. May 5.
Tesell’s presentation will describe PCSK9 inhibitors, a new class of drugs that lower LDL cholesterol levels, which may be the next pharmaceutical blockbuster because of the drugs’ cost and potential for use in a large number of patients with uncontrolled cholesterol. The evidence-based session at the summit will review data supporting the use of the drugs and their potential role in cholesterol management, detail the drugs’ current effect on patients, providers and payers in the U.S., and predict the potential impact of the drugs in light of cardiovascular trials that could support the drugs’ benefits.
Clinical Pharmacy Services is partnering with Asembia, formerly Armada Health Care, to provide enhancements and support on clinical protocols and therapy interventions to the Asembia1 technology platform. Its team includes more than 60 clinical pharmacists, as well as pharmacy associates and support staff with backgrounds in academia, direct patient care and managed care programs.
Clinical Pharmacy Services has become a sought-after partner for organizations seeking results-oriented solutions to containing pharmacy costs and improving patient outcomes. As part of UMass Medical School, it is able to provide direct access to clinical resources and the latest research, data and trends.